128. A pharmaceutical composition comprising

a therapeutically effective human dose of an immunogenic first peptide derived from a cancer associated antigen

wherein said peptide comprises an epitope of 8-11 amino acids, wherein said epitope has the amino acid V, A or T at position 2 and the amino acid L, I, V, M or A at its carboxy terminus;

said peptide coupled to a second peptide which second peptide is not derived from said cancer associated antigen and wherein said additional peptide is a Pan DR binding peptide.

- 129. The composition of claim 128 wherein said first peptide contains less than about 15 amino acid residues.
- 130. The composition of claim 128 wherein said peptide has V at position 2 and L at the C-terminus.
- 131. The compound of claim \\ 28' wherein said first peptide has V at position 2 and I at the C-terminus.
- 132. The compound of claim 128 wherein said first peptide has V at position 2 and V at the C-terminus.
- 133. The compound of claim 128/wherein said first peptide has V at position 2 and M at the C-terminus.
- 134. The compound of claim 128 wherein said first peptide has V at position 2 and A at the C-terminus.
- 135. The compound of claim 128 wherein said first peptide has A at position 2 and L at the C-terminus.
- 136. The compound of claim 128 wherein said first peptide has A at position 2 and I at the C-terminus.

- 137. The compound of claim 128 wherein said first peptide has A at position 2 and V at the C-terminus.
- 138. The compound of claim 128 wherein said first peptide has A at position 2 and M at the C-terminus.
- 139. The compound of claim 128 wherein said first peptide has A at position 2 and A at the C-terminus.
- 140. The compound of claim 128 wherein said first peptide has T at position 2 and L at he C-terminus.
- 141. The compound of claim 128 wherein said first peptide has T at position 2 and I at the C-terminus.
- 142. The compound of claim 128 wherein said first peptide has T at position 2 and V at the C-terminus.
- 143. The compound of claim 128 wherein said first peptide has T at position 2 and M at the C-terminus.
- 144. The compound of claim 128 wherein said first peptide has T at position 2 and A at the C-terminus.
  - 145. The peptide of claim 137 which is KMADLVGFLV.